PhaseRx filed for Chapter 11 protection with the U.S. Bankruptcy Court in the District of Delaware, case number 17-12890. The Company, which develops pharmaceuticals focused on the treatment of inherited enzyme deficiencies in the liver, is represented by Christopher A. Ward of Polsinelli.
PhaseRx announced its intentions to continue to manage and operate its business. The Company is working with Cowen and Company to “review financial and strategic alternatives with the goal of maximizing stockholder value.”
Robert W. Overell, Ph.D., president and C.E.O. of PhaseRx, comments, “The protection afforded under a Chapter 11 filing enables us to continue to explore strategic alternatives, including a potential merger transaction.”
Read more biopharmaceutical bankruptcy news.
The post PhaseRx Chapter 11 Bankruptcy appeared first on Daily Bankrupt Company Updates | Bankrupt Company News.